<DOC>
	<DOCNO>NCT02917057</DOCNO>
	<brief_summary>Exenatide weekly ( Bydureon ) approve January 2012 FDA USA treatment type 2 diabetes mellitus . Evidence clinical trial suggest Bydureon improves glucose control low risk hypoglycemia . Bydureon require dose titration necessary glucagon-like peptide-1 agonist , appear advantage , reduce insulin resistance , reduce weight , improve blood pressure lipid profile . However , degree advantage Bydureon lead improve outcome customary clinical care patient mild moderate renal impairment elderly patient unknown . The aim study evaluate effectiveness tolerability Bydureon relative basal insulin initiate first-ever injectable therapeutic regimen among elderly patient patient renal impairment . Patients initiated treatment Bydureon basal insulin July 2011 March 2015 recruit study cohort Optum 's database electronic health record . The two treatment cohort match propensity score method . Changes HbA1c , weight , marker renal function ( estimate glomerular filtration rate ( eGFR ) , serum creatinine , albumin/creatinine ratio ( ACR ) ) , incidences gastrointestinal symptom hypoglycaemia investigated patient different eGFR category different age .</brief_summary>
	<brief_title>Subanalyses Elderly Type 2 Diabetes Patients Type 2 Diabetes Patients With Renal Impairment</brief_title>
	<detailed_description>Background : In January 2012 , US Food Drug Administration approve once-weekly form exenatide , Bydureon , treatment type 2 diabetes mellitus . Evidence clinical trial suggest Bydureon improves glucose control low risk hypoglycemia . Bydureon require dose titration necessary glucagon-like peptide-1 agonist ( GLP-1RAs ) , appear advantage , reduce insulin resistance , reduce weight , improve blood pressure lipid profile . However , degree advantage Bydureon lead improve outcome patient renal impairment elderly unknown . Aims : The aim study evaluate effectiveness tolerability Bydureon relative basal insulin initiate first-ever injectable therapeutic regimen among elderly patient patient renal impairment . The specific study objective follow : - To quantify effectiveness Bydureon initiation relative initiation basal insulin , improve : - Glycated hemoglobin ( HbA1c ) - Weight ( body mass index ( BMI ) ) - HbA1c simultaneous reduction weight - Blood pressure lipid profile - To examine tolerability Bydureon initiation relative initiation basal insulin , occurrence : - Hypoglycemia - Gastrointestinal symptom ( nausea , vomit , diarrhea , constipation ) - Change marker renal function ( estimate glomerular filtration rate ( eGFR ) , serum creatinine , albumin/creatinine ratio ( ACR ) , stability liver function test ( AST , ALT ) standard blood count ( WBC , RBC , HCT , Hgb , PLT ) - To examine measure effectiveness tolerability within potentially vulnerable subgroup Bydureon basal insulin initiator : - T2D patient renal impairment - Elderly T2D patient Study Population Design : This retrospective cohort study use Optum 's EHR data July 2011 March 2015 identify injectable-naive T2D patient initiate either Bydureon basal insulin accrual period , January 2012 January 2015 . Injectable-naive T2D patient indetified . Propensity score method use match Bydureon initiator basal insulin initiator . Subgroup Comparisons : Within EHR data , serum creatinine value use calculate eGFR use equation develop Chronic Kidney Disease ( CKD ) Epidemiology ( EPI ) Collaboration , call CKD-EPI Equation . Renal Impairment : Patients stratify eGFR range baseline indicative renal impairment , follow : - Normal , eGFR â‰¥ 90.00 mL/min/1.73m2 - Mild impairment , 60.00 &lt; eGFR &lt; 89.99 mL/min/1.73m2 - Moderate Severe impairment , eGFR &lt; 59.99 mL/min/1.73m2 Elderly T2D Patients : Elderly subgroup define 65+ year age . Patients stratify age index date , follow : - &lt; 65 year - 65 74 year - 75+ year Outcomes Analysis : To measure effectiveness Bydureon relative basal insulin change HbA1c body weight , well change HbA1c simultaneous reduction weight . Changes BMI , lipid profile , blood pressure assess . These variable part clinical laboratory data EHR . Each outcome evaluate completeness , multiply impute , report across standardized time interval . HbA1c , weight BMI summarize baseline quarterly ( 3-month interval ) first year follow drug initiation . Lipid measurement blood pressure summarize baseline bi-annually ( 6-month interval ) first year follow drug initiation . To assess drug tolerability , incidence hypoglycemia , gastrointestinal symptom ( nausea , vomit , diarrhea , constipation ) calculate . These outcome ascertain use ICD-9 algorithm apply structured field extract mention hypoglycemia use natural language processing ( NLP ) algorithm develop Optum apply free text clinical note available data . In addition stability renal function evaluate change eGFR , albumin/creatinine ratio ( ACR ) ; change serum hepatic enzyme [ aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ] , hematologic measure [ red blood cell count ( RBC ) , white blood cell count ( WBC ) , platelet ( PLT ) , hemoglobin ( Hgb ) hematocrit ( Hct ) evaluate . Each laboratory value evaluate completeness , multiply impute , report across standardized time interval . eGFR ACR summarized baseline quarterly ( 3-month interval ) first year follow drug initiation . Hepatic enzyme hematologic measure summarize baseline semi-annually ( 6-month interval ) first year follow drug initiation .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>At least 18 year old ; receive care document EHR ( include least one outpatient provider visit ) minimum 6months prior index date ; least one diagnosis Type 2 diabetes ( ICD9CM : 250.X0 250.X2 ) prior include date study drug initiation , prior diagnosis type1 diabetes ( ICD9CM : 250.X1 250.X3 ) , gestational diabetes within 6months prior index date ; No evidence prior injectable antidiabetic treatment , specifically dispense GLP1RA insulin 6months baseline period prior study drug initiation Prior diagnosis type 1 diabetes ( ICD9CM : 250.X1 250.X3 ) , gestational diabetes within 6months prior index date ; Prior dispense GLP1RA insulin Missing data renal function define eGFR age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>